According to the Articles of Association of RaySearch Laboratories AB (publ), holders of Class A shares are entitled to request conversion of their shares into Class B shares. Each Class A share carries ten votes, while each Class B share carries one vote. During December, at the request of shareholders, a total of 2,171,738 Class A shares were converted into 2,171,738 Class B shares.
Following the conversion, as of 30 December 2025 (the last trading day of the month), the total number of shares amounted to 34,282,773, of which 3,483,237 were Class A shares and 30,799,536 were Class B shares. The total number of votes in the company thereafter amounted to 65,631,906.
For more information, please contact
Carolina Strömlid, Head of Investor Relations
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch’s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.